Document Detail


Enteral iron supplementation in preterm and low birth weight infants.
MedLine Citation:
PMID:  22419305     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Preterm infants are at risk of exhausting their body iron stores much earlier than healthy term newborns. It is widespread practice to give enteral iron supplementation to preterm and low birth weight infants to prevent iron deficiency anaemia. However, it is unclear whether supplementing preterm and low birth weight infants with iron improves growth and neurodevelopment. It is suspected that excess exogenous iron can contribute to oxidative injury in preterm babies, causing or exacerbating conditions such as necrotising enterocolitis and retinopathy of prematurity. Additionally, the optimal dose and timing of commencement and cessation of iron supplementation are uncertain.
OBJECTIVES: To evaluate the effect of prophylactic enteral iron supplementation on growth and neurodevelopmental outcomes in preterm and low birth weight infants. The secondary objectives were to determine whether iron supplementation results in improved haematological parameters and prevents other causes of morbidity and mortality.
SEARCH METHODS: We used the standard search strategy of the Cochrane Neonatal Review Group. We searched Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2011, Issue 8), MEDLINE (1951 to August 2011), CINAHL (1982 to August 2011) and conference proceedings and previous reviews.
SELECTION CRITERIA: Randomised controlled trials (RCTs) and quasi-randomised trials that compared enteral iron supplementation with no iron supplementation, or different regimens of enteral iron supplementation in preterm or low birth weight infants or both.
DATA COLLECTION AND ANALYSIS: We extracted data using the standard methods of the Cochrane Neonatal Review Group. Both review authors separately evaluated trial quality and data extraction. We synthesised data using risk ratios (RRs), risk differences (RDs) and weighted mean differences (WMDs). Where data about the methodology and results or both were lacking, we made an attempt to contact the study authors for further information.
MAIN RESULTS: We included twenty-six studies (2726 infants) in the analysis. The heterogeneity of participants, methods and results precluded an extensive quantitative synthesis. Of the 21 studies comparing iron supplementation with controls, none evaluated neurodevelopmental status as an outcome. Of thirteen studies reporting at least one growth parameter as an outcome, only one study of poor quality found a significant benefit of iron supplementation. Regarding haematological outcomes, no benefit for iron supplementation was demonstrated within the first 8.5 weeks of postnatal life (16 trials), except by two poor quality studies. After this age, most studies reported a higher mean haemoglobin in iron-supplemented infants. We were only able to include a limited number of studies in a quantitative meta-analysis, which suggested the haemoglobin concentration in iron-supplemented infants was higher by about 6 g/L at six to nine months. One study comparing high dose and low dose iron supplementation monitored neurodevelopmental outcome for one year, without finding any significant difference between the groups. One study comparing early versus late commencement of iron supplementation found no difference in cognitive outcome, but an increased rate of abnormal neurological examination in the late iron group at five years of age. The studies comparing high and low doses of iron indicated that there was no discernible haematological benefit in exceeding 'standard' doses of iron (i.e. 2 mg/kg/day to 3 mg/kg/day).
AUTHORS' CONCLUSIONS: The available data suggest that infants who receive iron supplementation have a slightly higher haemoglobin level, improved iron stores and a lower risk of developing iron deficiency anaemia when compared with those who are unsupplemented. However, it is unclear whether iron supplementation in preterm and low birth weight infants has long term benefits in terms of neurodevelopmental outcome and growth. The optimum timing and duration of iron supplementation remains unclear.
Authors:
Ryan John Mills; Mark W Davies
Related Documents :
3414365 - Assessment of the relative locations of the greater palatine foramen in adult chinese s...
6738695 - Vitamin e protects against retinopathy of prematurity through action on spindle cells.
2641435 - Incidence of cleft lip and/or palate in aichi prefecture. comparison of the incidence i...
1450195 - Correction of the bilateral cleft lip nasal deformity: evolution of a surgical concept.
1797495 - Relationship between normal oral glucose tolerance test in women at risk for gestationa...
3415895 - The morphine hydrogel suppository. a new sustained release rectal preparation.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-03-14
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  3     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2012  
Date Detail:
Created Date:  2012-03-15     Completed Date:  2012-06-07     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD005095     Citation Subset:  IM    
Affiliation:
Department of Paediatrics, Logan Hospital and University of Queensland, Loganholme DC, Australia. Ryan Mills@health.qld.gov.au.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Child Development / drug effects*,  physiology
Dietary Supplements*
Enteral Nutrition
Erythrocytes / cytology,  drug effects
Hemoglobin A / metabolism
Humans
Infant
Infant, Low Birth Weight / blood,  growth & development*
Infant, Newborn
Infant, Premature / blood,  growth & development*
Iron / administration & dosage*,  blood
Randomized Controlled Trials as Topic
Chemical
Reg. No./Substance:
7439-89-6/Iron; 9034-51-9/Hemoglobin A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sodium channel blockers for cystic fibrosis.
Next Document:  Patient education for neck pain.